Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic developments in multiple sclerosis.
Goodin DS. Goodin DS. Expert Opin Investig Drugs. 2000 Apr;9(4):655-70. doi: 10.1517/13543784.9.4.655. Expert Opin Investig Drugs. 2000. PMID: 11060700 Review.
HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.
Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL; Multiple Sclerosis Genetics Group. Barcellos LF, et al. Among authors: goodin ds. Am J Hum Genet. 2003 Mar;72(3):710-6. doi: 10.1086/367781. Epub 2003 Jan 28. Am J Hum Genet. 2003. PMID: 12557126 Free PMC article.
Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.
Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL. Oksenberg JR, et al. Am J Hum Genet. 2004 Jan;74(1):160-7. doi: 10.1086/380997. Epub 2003 Dec 10. Am J Hum Genet. 2004. PMID: 14669136 Free PMC article.
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis.
Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. Baranzini SE, et al. Among authors: goodin ds. Hum Mol Genet. 2009 Feb 15;18(4):767-78. doi: 10.1093/hmg/ddn388. Epub 2008 Nov 14. Hum Mol Genet. 2009. PMID: 19010793 Free PMC article.
Switching multiple sclerosis patients with breakthrough disease to second-line therapy.
Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Castillo-Trivino T, et al. Among authors: goodin ds. PLoS One. 2011 Feb 3;6(2):e16664. doi: 10.1371/journal.pone.0016664. PLoS One. 2011. PMID: 21304907 Free PMC article.
193 results